Phase II trial of neo-adjuvant chemohormonal therapy combining LHRH agonist and estramustine phosphate evaluating PSA failure free survival and safety for locally advanced prostate cancer
Phase 2
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000001660
- Lead Sponsor
- Hirosaki University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)patients with severe co-morbidity including uncontrollable cardiac, cerebral disease. 2)patients with serious liver dysfunction or serious blood disease. 3)patients with gastroenterial ulcer. 4)Patients who had hypersensitivity to Goserelin or Leuprorelin. 5)patients who fall under the followings: AST, ALT and ALP > 2.5 times upper limit of normal (ULN), Serum creatinine > 1.5 times ULN , Leukocyte count < 3,000/uL, Hemoglobin < 10.0g/dL, Platelet count < 75,000/uL 6)Patients with other cancer requiring treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method